- Cross-Border E-commerce Appearance Infringement Query
- Named Entity Recognition
- OCR Recognition
- Life Science Intelligent Data Governance
Life Science Intelligent Data Governance
Convert pictures of PDFs into editable text, then extract two types of Named Entities: organization and DDT (Drug, Disease, and Target) with their correlations from the text; and display related information in Patsnap meta database when clicking on each Named Entity.
Log in to try, click toLogin/Register
INDIANAPOLIS, June 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1. The primary endpoints of the study were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
BMS抢滩成功，刺激了相关竞品的交易。同年12月，武田与Nimbus达成40亿美元预付款、20亿美元里程碑款的合作，引进后者的TYK2抑制剂NDI-034858（TAK-279）。5月，武田已启动TAK-279治疗中重度斑块状银屑病的两项国际多中心III期临床研究。
武田的心思，其实与Alumis等Biotech那句“best-in-class TYK2抑制剂”的口号类似。BMS开发Sotyktu过程用到氘代技术，可一些科学家认为，这种变构的挪腾空间不大。换言之，Sotyktu尚有改进空间。
临床前研究中，TAK-279表现出比Sotyktu更强的选择性。根据IIb期临床结果，该候选药物治疗组达到主要终点——PASI 75（银屑病面积和严重程度指数改善75%）的患者比例显著高于对照组。
2024年6月12日，勃林格殷格翰宣布，survodutide（BI 456906）获得中国国家药品监督管理局（NMPA）药品审评中心（CDE）突破性疗法认定，拟用于代谢功能障碍相关脂肪性肝炎（MASH）的治疗。
Survodutide是一种具有独特作用机制的胰高血糖素受体/胰高血糖素样肽-1受体（GCGR/GLP-1R）双重激动剂。Survodutide中的胰高血糖素受体激动剂组分能够增加能量消耗，并且直接对肝脏产生影响，有助于改善肝纤维化；GLP-1受体激动剂组分则能有效降低食欲，同时增加饱腹感。II期临床试验显示，与安慰剂相比，接受survodutide (BI 456906) 治疗的MASH成人患者实现了具有统计学意义的组织学和纤维化改善（83% vs 18.2%）。